CDP choline (also called citicoline) is a choline source your brain uses to build cell membranes and to make acetylcholine, the neurotransmitter that runs attention, learning, and memory. Most people take it as a daily nootropic for sharper focus and more reliable mental stamina, particularly when work demands sustained attention over hours rather than short bursts.
It's not a stimulant. The effect builds over weeks, not minutes. At 250-500 mg/day, the typical experience is that focus holds longer, mental fatigue sets in later, and recall feels slightly more available. The same pathways are also why it's been studied for age-related memory decline, glaucoma, and stroke recovery, which gives it a deeper evidence base than most cognitive supplements.
Deep-dive
Once ingested, citicoline hydrolyses in the gut and liver into its two components, choline and cytidine, both of which are highly bioavailable (oral bioavailability is around 90%, comparable to IV dosing). Cytidine converts to uridine in human blood, and both choline and uridine cross the blood-brain barrier separately. Inside neurons they're recombined back into CDP choline, which feeds two distinct downstream pathways. This dual-substrate behaviour is what separates citicoline from other choline forms.
The first pathway is the Kennedy cycle, which uses CDP choline to synthesise phosphatidylcholine, the main phospholipid in every neuronal membrane. This is structural: it supports membrane repair, synapse formation, and the integrity of axons. The second pathway is acetylcholine synthesis, since choline is the rate-limiting substrate. Citicoline also appears to modulate dopamine release via stimulation of tyrosine hydroxylase, raises noradrenaline in the CNS, and stimulates glutathione synthesis, all of which are relevant to its neuroprotective profile. A 2024 review in The FASEB Journal covers the mechanism in detail.
Brain energy and membrane turnover. A 2008 phosphorus MRS imaging study at Harvard gave 16 healthy adults 500 mg or 2000 mg of citicoline for 6 weeks and measured a 14% increase in ATP and a 7% rise in phosphocreatine in the anterior cingulate cortex, alongside a 26% increase in membrane phospholipid turnover. The anterior cingulate is the region most associated with attention and effortful focus, and the changes were specific to that region, the parieto-occipital cortex showed nothing. This is the most direct evidence that citicoline is doing something measurable to brain energy metabolism, not just changing self-reported mood.
Memory in healthy older adults. A 2021 randomised trial of 100 healthy men and women aged 50-85 with age-associated memory impairment gave 500 mg/day for 12 weeks. The citicoline group showed significant improvements in composite memory score and paired associates learning compared to placebo. Effect sizes were modest but clean, and the trial included roughly equal numbers of men and women.
Attention in healthy adults. A 2012 trial in healthy women aged 40-60 found 250 mg and 500 mg over 28 days both improved attention, with the higher dose producing slightly larger gains. A study in healthy adolescent males (250 or 500 mg for 28 days) showed improved attention, faster psychomotor speed, and reduced impulsivity, with weight-adjusted dose predicting most of the effect. A pilot ADHD trial in children found citicoline was well-tolerated and showed early signal on attention and impulsivity scales, though sample sizes were small.
Stroke and vascular cognitive impairment. This is where the evidence is most mixed. Older meta-analyses (Saver 2008, Secades 2016) found citicoline reduced death and dependency after ischemic stroke. The large 2012 ICTUS trial of 2298 patients found no benefit on top of modern stroke care, which the authors attributed to better baseline treatment diluting the effect. A more recent 2025 network meta-analysis of 13 trials concluded that 2000 mg/day showed the lowest mortality and best neurological recovery vs control. For mild vascular cognitive impairment specifically, evidence remains supportive.
Glaucoma. Citicoline (oral or eye drops) has been studied as a neuroprotective adjunct for primary open-angle glaucoma, where intraocular pressure reduction alone often doesn't halt disease progression. A 2-year pilot in 60 patients using 500 mg/day oral citicoline cyclically showed slower visual field deterioration and better retinal nerve fibre layer preservation. Studies are small and not blinded as cleanly as one would want, but the mechanism is plausible and the safety profile is forgiving.
Women. Choline metabolism is sex-different in a way that matters for this compound. Oestrogen upregulates PEMT, the enzyme that synthesises choline endogenously in the liver, which is why premenopausal women are partially protected from dietary choline deficiency while men and postmenopausal women are not. Practically, this means premenopausal women may be slightly less choline-limited at baseline, but it does not mean they get nothing from supplementation. The memory study in older adults and the attention trial in women aged 40-60 both showed clear cognitive benefit. Postmenopausal women, who lose the oestrogen-driven PEMT boost, are likely to benefit most. Women who are pregnant or breastfeeding have substantially elevated choline requirements, and citicoline is a reasonable supplemental form, but should only be used under clinical guidance during pregnancy.
Citicoline vs alpha-GPC vs choline bitartrate. Choline bitartrate is cheap and poorly bioavailable to the brain, fine for general dietary choline but not effective as a nootropic. Alpha-GPC delivers more choline per milligram (roughly 40% by weight vs citicoline's 18-19%) and acts faster on acetylcholine, which is why it's favoured for acute pre-workout or pre-task use. Citicoline is slower-onset but contributes both choline and uridine, supporting membrane synthesis and brain energy in addition to acetylcholine, which is why it's the better-evidenced choice for chronic cognitive support and neuroprotection. They're not interchangeable, they cover different use cases. A separate consideration: choline from food sources (eggs, meat, phosphatidylcholine supplements) is more readily metabolised by gut bacteria into trimethylamine and TMAO, which has been linked to cardiovascular risk in observational data. Citicoline appears to be less prone to this conversion, though direct head-to-head TMAO comparisons in humans are still limited.
Limitations. Most of the well-designed cognitive trials have been funded by Kyowa Hakko, the manufacturer of Cognizin (the most studied branded form). The findings are consistent and the methodology is sound, but independent replication is sparser than ideal. The healthy-adult cognitive effects are real but modest, this is not a compound that produces dramatic subjective changes. The neuroprotective claims for slowly progressing conditions (glaucoma, mild vascular cognitive impairment) are more promising than the acute stroke literature, which has been muddied by improvements in standard stroke care.
Dosage:
- Standard cognitive dose: 250-500 mg/day, taken once in the morning. Most cognitive trials in healthy adults use 500 mg/day for 4-12 weeks. Effect builds gradually, expect 2-4 weeks before you notice a steady difference
- Higher-dose protocols: 1000-2000 mg/day, split into two doses (morning and early afternoon), used in clinical settings for vascular cognitive impairment, stroke recovery, and glaucoma. Usually run cyclically (e.g., 4 months on, 2 months off) for chronic conditions
- Timing: Morning or early afternoon. Citicoline is mildly activating for some people and can interfere with sleep if taken late. Food doesn't significantly affect absorption, take it with or without
- Forms: Cognizin is the patented form used in most clinical trials, well-characterised but expensive. Generic citicoline (often called CDP choline) is chemically identical and considerably cheaper. Both work. Avoid choline bitartrate as a nootropic, it's cheaper but doesn't deliver choline efficiently to the brain
- Women's notes: Premenopausal women may notice less effect than men or postmenopausal women at the same dose, because oestrogen-driven endogenous choline synthesis raises baseline. Postmenopausal women often benefit from the higher end of the cognitive range (500 mg). Pregnancy and lactation increase choline demand substantially, but supplement only with clinical guidance during these periods
- Stacks: Pairs cleanly with caffeine for sustained focus without the choline-deficiency edge that some people get from heavy caffeine alone. Pairs with L-tyrosine for stress and cognitive load. The classic nootropic stack of citicoline + caffeine + L-theanine is well-tolerated and covers acetylcholine, dopamine modulation, and the calming side of the equation
- Cycling: Not strictly necessary for daily use at 250-500 mg, the safety profile holds out to 12 months in trials. Some people prefer 8 weeks on, 2 weeks off to retain subjective sensitivity
Here's what you can expect:
For the first 1-2 weeks, most people feel little or nothing. By weeks 3-4, you should notice that focus holds longer through the workday, mental fatigue arrives later, and you have slightly easier access to words and recall. It's a noticeable shift in stamina rather than a peak experience. Don't expect Adderall-style effects, that's not the mechanism.
If you're using it for memory in your 50s or beyond, the realistic expectation is small but real improvement on tasks that depend on encoding and retrieval, the kind of changes that show up on cognitive tests rather than feel dramatic day-to-day. Trial data points to meaningful gains at 12 weeks of consistent use.
If you take it expecting a stimulant or a fast-onset cognitive enhancer, you'll be disappointed. The compound rewards consistency. Skipping doses doesn't crash you, but the benefit fades within a couple of weeks of stopping.
Side effects & risks:
- GI discomfort is the most common side effect at higher doses (1000+ mg). Nausea, loose stools, mild abdominal pain. Usually resolves by splitting the dose or taking with food
- Headache in a small minority, often resolves within a week or with a lower dose
- Insomnia or vivid dreams if taken too late in the day. Mechanism is the mild dopaminergic and noradrenergic activation. Switch to morning dosing if this happens
- Mild blood pressure changes have been reported in some trials, usually a small drop. Caution if you're already on antihypertensives
- Bipolar disorder caution. Citicoline raises dopamine and noradrenaline activity. There is no strong signal in the trial literature linking it to mania, and a recent meta-analysis didn't support earlier concerns about psychiatric drug interactions, but if you have a history of bipolar disorder or psychotic illness, run it past a clinician first
- Levodopa interaction. Citicoline has been studied as an adjunct to levodopa in Parkinson's and may allow lower levodopa doses, but it's not something to combine without specialist input
- Thyroid. No direct interaction with thyroid hormone, but if you're on thyroid medication or have an active thyroid condition, no specific concerns are documented
- Pregnancy and breastfeeding. Choline demand is high during these periods and citicoline is a reasonable supplemental form, but doses above standard pregnancy choline recommendations should be cleared with a clinician first. Most pregnancy guidance focuses on choline bitartrate or phosphatidylcholine rather than citicoline specifically
- TMAO consideration. All choline sources contribute to gut-derived TMAO production, which is associated with cardiovascular risk in observational data. Citicoline appears less susceptible to this conversion than choline bitartrate or phosphatidylcholine, but if you have established cardiovascular disease and want to be cautious, baseline and follow-up TMAO can be measured
- Long-term safety. Trials up to 12 months at 500-2000 mg/day have shown an excellent safety profile across thousands of patients. Beyond a year, controlled human data thins, but decades of clinical use in stroke and dementia populations haven't surfaced significant red flags
Blood markers
Homocysteine, baseline if you're starting citicoline for cognitive or neuroprotective use. Choline metabolism intersects with the methylation cycle and elevated homocysteine is independently a risk factor for cognitive decline. If high, address B12, folate, and B6 alongside citicoline. Recheck at 3-6 months
Lipid panel, baseline. Citicoline itself doesn't have a clear lipid signal, but the broader choline-TMAO question is relevant if you have cardiovascular risk factors. A baseline gives you context if you decide to look at TMAO later
TMAO is optional but worth measuring at baseline and at 3 months if you have established cardiovascular disease, family history, or are running higher chronic doses. It's not in standard panels, request specifically
Liver enzymes (ALT, AST) baseline if you're going to run 1000+ mg/day chronically. No specific evidence of hepatotoxicity, but routine baseline is good practice for any long-term supplement at the higher end of dosing
For most people taking 250-500 mg/day for cognitive support, no specific bloodwork is needed.
Sold as a dietary supplement in most countries; in some (Japan, parts of Europe and Latin America) it's also a prescription drug for cognitive impairment and stroke recovery.
Made with Bullet